Biphasic and Stage-Associated Expression of CPEB4 in Hepatocellular Carcinoma

PLoS One. 2016 May 9;11(5):e0155025. doi: 10.1371/journal.pone.0155025. eCollection 2016.

Abstract

Cytoplasmic polyadenylation element binding protein 4 (CPEB4) is a sequence-specific RNA-binding protein and translational regulator, with expression associated with tumor progression. Nevertheless, CPEB4 seems to play paradoxical roles in cancers-an oncogenic promoter in pancreatic ductal adenocarcinoma (PDA) and glioblastomas but a tumor suppressor in hepatocellular carcinoma (HCC). To assess whether CPEB4-regulated carcinogenesis is tissue-specific, we reevaluated the role of CPEB4 in HCC. Although proliferation of hepatocytes appeared normal in CPEB4-knockout (KO) mice after partial hepatectomy, knockdown (KD) of CPEB4 in HepG2 liver cancer cells promoted colony formation in vitro. Moreover, the growth of CPEB4-KD cells was accelerated in an in vivo xenograft mouse model. In tumorous and adjacent non-tumorous paired liver specimens from 49 HCC patients, the protein level of CPEB4 was significantly upregulated in early-stage HCC but decreased toward late-stage HCC. This finding agrees with changes in CPEB4 mRNA level from analysis of two sets of HCC microarray data from the Gene Expression Omnibus (GEO) database. Taken together, downregulation of CPEB4 likely occurs at the late cancer stage to facilitate HCC progression. Biphasic alteration of CPEB4 expression during HCC progression suggests its complicated role in tumorigenesis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Animals
  • Carcinoma, Hepatocellular / metabolism*
  • Female
  • Heterografts
  • Humans
  • Liver Neoplasms / metabolism*
  • Male
  • Mice
  • Mice, Knockout
  • Middle Aged
  • RNA-Binding Proteins / genetics
  • RNA-Binding Proteins / immunology
  • RNA-Binding Proteins / metabolism*

Substances

  • CPEB4 protein, human
  • RNA-Binding Proteins

Grants and funding

This work was supported by Tzu Chi General Hospital [TCRD10322 and TCRD10445 to CFC], https://www.tzuchi.com.tw/tzuchi_en/default.aspx; Academia Sinica [AS103TPB05 to YSH], https://www.sinica.edu.tw/main_e.shtml; the Taiwan Ministry of Science and Technology [MoST 1032325B303001 to CFC and MoST 1022628B001007MY3 to YSH], https://www.most.gov.tw/en/public. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Mao Ying Genetech Inc. provided support in the form of salaries for authors [PIH], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the ‘author contributions’ section.